Scope Fluidics SA (SCP) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.102x

Based on the latest financial reports, Scope Fluidics SA (SCP) has a cash flow conversion efficiency ratio of -0.102x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-11.75 Million ≈ $-3.23 Million USD) by net assets (zł115.43 Million ≈ $31.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Scope Fluidics SA balance sheet independence to measure how much of total assets are equity-financed.

Scope Fluidics SA - Cash Flow Conversion Efficiency Trend (2015–2024)

This chart illustrates how Scope Fluidics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Scope Fluidics SA to evaluate the quality of earnings relative to operating cash generation.

Scope Fluidics SA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Scope Fluidics SA ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Putra Mandiri Jembar Tbk PT
JK:PMJS
0.030x
I Jang Industrial Co Ltd
TWO:8342
0.118x
Kuen Ling Refrigerating Machinery Co Ltd
TWO:4527
-0.010x
Netas Telekomunikasyon AS
IS:NETAS
0.222x
Shinsegae Food
KO:031440
-0.062x
Phoenix Group Holdings PLC
LSE:PHNX
4.726x
Cemacon Zalau
RO:CEON
N/A
CO2 Energy Transition Corp. Unit
NASDAQ:NOEMU
-0.002x

Annual Cash Flow Conversion Efficiency for Scope Fluidics SA (2015–2024)

The table below shows the annual cash flow conversion efficiency of Scope Fluidics SA from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Scope Fluidics SA worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 zł146.35 Million
≈ $40.28 Million
zł-25.10 Million
≈ $-6.91 Million
-0.172x +27.15%
2023-12-31 zł80.93 Million
≈ $22.27 Million
zł-19.06 Million
≈ $-5.24 Million
-0.235x -178.45%
2022-12-31 zł332.97 Million
≈ $91.64 Million
zł-28.16 Million
≈ $-7.75 Million
-0.085x +94.44%
2021-12-31 zł14.58 Million
≈ $4.01 Million
zł-22.19 Million
≈ $-6.11 Million
-1.522x -215.52%
2020-12-31 zł33.09 Million
≈ $9.11 Million
zł-15.96 Million
≈ $-4.39 Million
-0.482x +6.93%
2019-12-31 zł20.22 Million
≈ $5.56 Million
zł-10.48 Million
≈ $-2.88 Million
-0.518x -23.38%
2018-12-31 zł12.81 Million
≈ $3.52 Million
zł-5.38 Million
≈ $-1.48 Million
-0.420x -43.76%
2017-12-31 zł16.88 Million
≈ $4.64 Million
zł-4.93 Million
≈ $-1.36 Million
-0.292x +57.84%
2016-12-31 zł5.58 Million
≈ $1.53 Million
zł-3.87 Million
≈ $-1.06 Million
-0.693x -966.74%
2015-12-31 zł6.70 Million
≈ $1.84 Million
zł535.69K
≈ $147.43K
0.080x --

About Scope Fluidics SA

WAR:SCP Poland Diagnostics & Research
Market Cap
$93.48 Million
zł339.65 Million PLN
Market Cap Rank
#19373 Global
#155 in Poland
Share Price
zł124.60
Change (1 day)
+7.79%
52-Week Range
zł113.00 - zł180.80
All Time High
zł341.00
About

Scope Fluidics S.A., a biotechnology company, designs and develops projects based on microfluidic technologies in medical diagnostics and healthcare in Poland. The company offers BacterOMIC, an antibiotic susceptibility testing. Scope Fluidics S.A. was founded in 2010 and is based in Warsaw, Poland.